The Madagascar healthcare system serves more than 31 million people across an island larger than France, with remote districts, weak transport links, and a heavy infectious disease burden. Madagascar is often discussed through biodiversity or plague outbreaks, but the health system story is broader: rural primary care access, maternal and child health, malaria, tuberculosis, undernutrition, rising cardiovascular disease, and a data system that is beginning to connect human, animal, and environmental health. For pharma, CROs, and public health organisations, healthcare in Madagascar is a reminder that geography can be as important as policy.
Madagascar Healthcare System at a Glance
Madagascar is a low-income country in the Indian Ocean with a dispersed population and major regional differences in access to care. WHO's country data lists a 2023 population of about 31.2 million and current health expenditure at roughly 3.5 percent of GDP in 2021. Those figures put Madagascar in the group of African systems where domestic financing, donor support, and out-of-pocket payments all shape what patients can actually receive.
The Ministry of Public Health steers the public system. Service delivery is organised through community-level services, basic health centres, district hospitals, regional referral hospitals, and national university hospitals. In practice, many patients face long travel times, stock-outs, user fees, and limited diagnostic capacity. Private providers and faith-based facilities help fill gaps, especially in urban areas and some mission-supported districts.
The country's disease profile is mixed. Communicable, maternal, neonatal, and nutritional conditions remain a major cause of death, while noncommunicable diseases account for a growing share of hospital demand. Our World in Data estimates that in 2023, communicable diseases caused about 111,000 deaths, NCDs about 93,500, and injuries about 26,700. That split captures the transition: Madagascar has not moved beyond infectious disease, but chronic disease is no longer secondary.
Health System Structure and Service Access
Primary care is delivered through Centres de Santé de Base, commonly known as CSB facilities. CSB I sites provide basic preventive and curative care, while CSB II facilities usually have more staff and a broader service package. District hospitals handle referrals, surgery, complicated deliveries, and inpatient care. Regional and university hospitals provide higher-level specialist services, concentrated in larger cities such as Antananarivo.
The model is sensible on paper. The challenge is reach. Roads, seasonal weather, mountainous terrain, and poverty turn referral into a real barrier. A patient in a remote commune may delay care until illness is severe because transport costs more than the consultation. For pregnant women, that delay can be fatal if obstructed labour, haemorrhage, or eclampsia develops far from emergency obstetric care.
Health financing adds another constraint. Madagascar has long pursued universal health coverage goals, but public funding remains limited. Out-of-pocket spending affects care-seeking and adherence, especially for chronic conditions that require repeat visits. Donor programmes support malaria, immunisation, nutrition, tuberculosis, HIV, and health security, but programme funding does not automatically create a stronger shared system.
Compared with mainland neighbours such as Tanzania, Madagascar's island geography makes national supply chain and referral planning unusually difficult. The country needs district-level visibility into medicines, laboratory capacity, staffing, and patient flows, not just national planning targets.
Disease Burden and Health Outcomes
Madagascar's disease burden is shaped by poverty, nutrition, climate, and ecology. Malaria remains a major public health issue, with transmission varying by region. Tuberculosis persists, and childhood respiratory infections and diarrhoeal disease remain important causes of illness and death. Undernutrition affects child development and raises risk across other diseases.
Plague is the disease most associated with Madagascar internationally. The country reports plague cases most years, mainly bubonic plague, with pneumonic outbreaks creating periodic emergency concern. The Institut Pasteur de Madagascar has played a central role in plague diagnostics and surveillance, including rapid tests and reference laboratory functions.
Maternal and neonatal health remain priorities. Facility delivery, skilled birth attendance, emergency referral, blood availability, and newborn care capacity vary by region. This is exactly where health-system averages hide risk. A district may report antenatal contacts while still lacking reliable emergency obstetric capacity.
NCDs are rising. Cardiovascular disease, stroke, diabetes, cancer, chronic respiratory disease, and kidney disease are increasingly visible in hospitals. A 2025 analysis of multimorbidity and mortality trends in Madagascar highlighted the interaction of chronic and infectious diseases across regions. That interaction matters clinically: a patient with hypertension and tuberculosis, or diabetes and infection, needs continuity that the acute-care model does not always provide.
Primary Care, Hospitals, and Workforce Constraints
Madagascar's primary care system is the first line for immunisation, antenatal care, malaria treatment, childhood illness, family planning, nutrition, and basic outpatient services. Community health workers extend reach in rural areas, but their effectiveness depends on supervision, commodity supply, referral links, and whether data flows back to health centres.
Hospitals carry a heavy burden because primary care cannot always diagnose or manage patients early. District hospitals need surgery, obstetric care, inpatient paediatrics, blood services, laboratory capacity, oxygen, and referral transport. Regional and university hospitals need specialist staff and equipment, but they also absorb patients who could have been managed earlier if local services were stronger.
Workforce distribution is a persistent weakness. Health workers are concentrated in urban areas, while rural districts may rely on fewer staff with broad responsibilities. Retention is hard when facilities lack housing, supplies, supervision, and career paths. Training more workers helps, but deployment and support matter just as much.
The result is a system where patient-level data would be extremely valuable. Which patients bypass CSB facilities? Which referrals never arrive? Which facilities repeatedly stock out of malaria tests, antihypertensives, or antibiotics? Those questions cannot be answered well with national indicators alone.
Digital Health and Data Infrastructure
Digital health in Madagascar is moving toward stronger routine and surveillance systems. DHIS2 is an important platform, and in 2025 HISP UiO announced a partnership with Madagascar to develop a DHIS2-based One Health platform and interoperable laboratory information system. The focus is data sharing across human, animal, and environmental health.
That One Health direction fits Madagascar. Plague, zoonotic disease risk, climate-sensitive infections, and environmental change all require data that crosses sectors. A surveillance system that only sees facility reports will miss part of the picture.
The digital health challenge is integration. Routine service data, laboratory data, community reporting, disease surveillance, supply chain information, and patient records often sit in different workflows. Connectivity and staff time remain practical constraints. If a rural facility spends scarce time entering data that no one uses locally, reporting quality will suffer.
Madagascar can build from surveillance toward routine service analytics. That means using data not only to detect outbreaks but also to improve primary care, referrals, medicine availability, and chronic disease follow-up. Kapsule's work structuring de-identified health records across African markets points to the same principle: data becomes useful when it is clean enough, linked enough, and governed well enough to support decisions.
Clinical Research Capacity
Madagascar has credible research capacity in infectious disease, especially through the Institut Pasteur de Madagascar. The institute has research units and reference laboratories covering plague, tuberculosis, malaria, antimicrobial resistance, dengue, chikungunya, polio, Rift Valley fever, and other public health priorities.
The country also has experience in complex field research. In 2024, researchers from Madagascar and Oxford reported enrolling more than 220 patients in a randomised trial for bubonic plague treatment, an unusual achievement for a neglected disease with episodic cases. That kind of study requires surveillance links, clinical sites, laboratory support, and community trust.
Madagascar is not a large commercial trial market. Trial volumes are modest compared with South Africa, Egypt, or Kenya. But the country is important for studies in malaria, plague, tuberculosis, neglected tropical diseases, maternal and child health, nutrition, and climate-sensitive infectious disease. It may also become more relevant for real-world evidence as digital systems improve.
Sponsors need careful feasibility work. Site selection should assess transport, laboratory workflows, ethics capacity, cold chain, language, community engagement, and data quality. Madagascar is not a place for lazy extrapolation from mainland Africa.
For sponsors mapping clinical trials in Africa, Madagascar should be treated as a specialist market. It is not the largest recruitment geography, but it can answer questions that few countries can answer well, especially around plague, malaria, neglected infections, and One Health surveillance.
Opportunities for Health Data and Innovation
Madagascar needs health data that connects hard-to-reach care with better evidence. The system needs to understand district variation, rural access, referral delays, stock-outs, outbreak signals, and chronic disease follow-up. That is useful for ministries, donors, researchers, and companies.
For public health agencies, linked data can show where malaria control is lagging, where maternal referrals fail, and which districts need laboratory investment. For pharma and CROs, it can improve feasibility assessment for infectious disease and NCD studies. For market access teams, it can separate theoretical need from reachable demand.
The country also has a distinctive One Health case. Madagascar's disease ecology makes it a strong candidate for integrated surveillance that connects health facilities, laboratories, animal health, and environmental signals.
Kapsule provides access to structured, de-identified health records covering over 75 million patients across 14 African countries. Contact our team to discuss how Madagascar-style health data can support site feasibility, disease-burden analysis, and evidence planning across African markets.
This article is intended for informational purposes only and does not constitute legal, medical, or regulatory advice. Readers should obtain independent professional counsel for their specific circumstances.